Tryptamine Therapeutics (ASX:TYP) CEO Jason Carroll

Описание: In this Leadership Talks session, we speak with Jason Carroll, CEO of Tryptamine Therapeutics (ASX:TYP), a pioneering biotech company focused on precision-delivered psychedelic medicine. With over 30 years of life sciences leadership at Johnson & Johnson, Janssen, and Bristol Myers Squibb, Jason now leads TYP’s mission to transform treatment for complex neuropsychiatric and chronic pain conditions through its proprietary IV-administered psilocin therapy (TRP-8803).

Jason shares insights into Tryptamine’s innovative approach, near-term clinical milestones, and why the company’s focused pipeline could redefine how mental health and pain disorders are treated.

In this session, Jason covers key aspects of Tryptamine’s strategy:

✔ Precision Psychedelic Delivery
TRP-8803 bypasses the challenges of oral psilocybin with controlled IV infusion — enabling faster onset, reduced side effects, and full dose reversibility, giving physicians unprecedented control in psychedelic-assisted therapy.

✔ Targeting Underserved, High-Impact Conditions
TYP’s lead programs target binge eating disorder, fibromyalgia, and irritable bowel syndrome — conditions that affect millions globally, yet have seen little innovation. These three alone represent 45% of the total addressable neuropsychiatric market.

✔ Promising Early Data, Global Relevance Ahead
Tryptamine has already seen 80–100% response rates in early studies using oral psilocybin. Now, with a fully funded clinical program underway and recruitment starting with Swinburne University, TRP-8803 is poised to deliver pivotal data by year-end.

✔ Veteran Leadership with Pharma Credibility
From leading 1,000+ staff at J&J Vietnam to directing business development on blockbuster biologics, Jason brings proven operational and commercial expertise — and a personal investment of $1M — into a sector he once dismissed but now sees as the next wave in CNS therapeutics.

With a differentiated platform, global IP protection, and regulatory-ready data on the horizon, Tryptamine Therapeutics is building the blueprint for next-generation psychedelic medicine.

Follow Tryptamine Therapeutics on LinkedIn:
  / tryp-therapeutics  

Follow East Coast Research on LinkedIn:
  / east-coast-research  

Questions? Email: [email protected] or [email protected]

#TryptamineTherapeutics #ASXTYP #LeadershipTalks #PsychedelicTherapy #BiotechInnovation #MentalHealth #ChronicPain #Psilocybin #Neuropsychiatry #PrecisionMedicine #IVTherapy #LifeSciences #EastCoastResearch